DGXQuest Diagnostics Incorporated
AI adoption · Q1 2026 earnings call
Health CareScaling
10
extracted from this call
4 / 5
quantified with specifics
Not disclosed
no breakout in this call
Quest Diagnostics discussed AI across three primary domains: internal productivity (AI-assisted customer service email triage), patient-facing product (Quest AI Companion powered by Google Gemini on the MyQuest app), and laboratory automation (image digitization and algorithmic analysis of slides). Management cited a 40% productivity boost in customer service from AI email triage and approximately 350,000 patient engagements with the AI Companion since Q1 launch. The CEO also articulated a forward-looking vision of AI integrating wearable biometrics with lab biomarkers to transform the future of preventive care.
Adopter
See full leaderboard →64/ 100
78
stage: scaling · max spec: 4
40
2 quant outcomes
85
3 scopes
internal_useproduct_embeddedproduct_standalone
10 AI mentions from this call.
Extracted verbatim from the DGX Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T4Prepared remarks· CEO· Internal use
“we boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails to speed responses.”
— James Davis, DGX earnings call - T4Prepared remarks· CEO· Product-embedded AI
“Patients have engaged Quest AI Companion approximately 350,000 times since we rolled it out to users of our MyQuest app in the first quarter.”
— James Davis, DGX earnings callGoogleQuest AI Companion, MyQuest - T3Q&A· CEO· Internal useyou gave some interesting stats on AI and automation. And just how do we think about your targets or your goals on that front from an efficiency gain standpoint and what you can leverage from an AI use case?
“60%, 70% of our efforts are in the 4 walls of our laboratory because that's where still opportunity exists. Anytime we see somebody looking through a microscope, we ask the question, is what you're looking at? Can we digitize that image? If you can digitize an image, you can apply algorithms to that image. And if you can apply algorithms to that image, it can assist whoever is reading that image and make a higher quality diagnosis as well as improve the productivity.”
— James Davis, DGX earnings call - T3Q&A· CEO· Product-embedded AII wanted to talk about the convergence of multiple factors, AI, wearables, consumer-initiated testing.
“this past March, I believe it was March 13, there was a really interesting article written in Nature, some work that Google Health did. It was a study between us, Google Health and Fitbit that really highlighted the linkage between biometrics and biomarkers and the use of artificial intelligence to actually calculate some of these biomarkers in between lab tests.”
— James Davis, DGX earnings callGoogle Health, Fitbit - T3Prepared remarks· CEO· Standalone AI product
“Our new Quest AI Companion transforms complex biomarker data and reference ranges on test reports into clear plain language. By empowering patients with lab insights, our AI tool, which is powered by Google Gemini, can help shift the doctor-patient relationship to be focused on shared decision-making instead of data gathering, potentially improving care outcomes.”
— James Davis, DGX earnings callGoogleQuest AI Companion, MyQuest - T3Q&A· CEO· Product-embedded AIyou gave some interesting stats on AI and automation. And just how do we think about your targets or your goals on that front from an efficiency gain standpoint and what you can leverage from an AI use case?
“we did put that Quest AI assistant out on our MyQuest application. This empowers people to now ask questions about the lab results that we've just provided to you. And we were pleasantly surprised by the use of that AI tool for people trying to decipher what all of these 40, 50, 60 analytes could possibly mean.”
— James Davis, DGX earnings callQuest AI Companion, MyQuest - T3Prepared remarks· CEO· Internal use
“we grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI across our operations both in and outside our labs.”
— James Davis, DGX earnings call - T2Q&A· CEO· Customer demand signalI wanted to talk about the convergence of multiple factors, AI, wearables, consumer-initiated testing. Just given the fact that these AI wearables, et cetera, and consummation tested gamify longitudinal testing, it seems like there would be an increase in longitudinal testing.
“the future, the physical of the future is going to be really before you ever see the doctor, you're going to download your wearable information. You're going to get your lab work done ahead of time. And all that information is going to be fed into an AI engine and it's going to provide you the patient with a report. It's going to provide the physician with a report.”
— James Davis, DGX earnings call - T2Q&A· CEO· Internal useyou gave some interesting stats on AI and automation. And just how do we think about your targets or your goals on that front from an efficiency gain standpoint and what you can leverage from an AI use case?
“We've made tremendous progress in cytology. We've made great progress in microbiology, hematology, and there's still other areas for us to go.”
— James Davis, DGX earnings call - T2Prepared remarks· CEO· Internal use
“we also grew the bottom line with productivity benefits from automation and AI.”
— James Davis, DGX earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of total AI-related cost savings or contribution to the 3% Invigorate productivity target.
- No disclosure of capital expenditure specifically allocated to AI versus broader lab automation.
- No revenue attribution to AI-enabled products or services.
- When asked directly about AI targets and efficiency gain goals (Erin Wright, Morgan Stanley), management provided directional commentary on use cases but declined to provide specific financial targets or timelines for AI ROI.
- No disclosure of the number of customer service agents using AI email triage tool, limiting context for the 40% productivity figure.
- No disclosure of cost or investment associated with the Google Gemini partnership or Quest AI Companion development.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.